These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22012946)

  • 1. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
    Smith MA; Gorlick R; Kolb EA; Lock R; Carol H; Maris JM; Keir ST; Morton CL; Reynolds CP; Kang MH; Arts J; Bashir T; Janicot M; Kurmasheva RT; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):329-32. PubMed ID: 21922647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial testing of cisplatin by the pediatric preclinical testing program.
    Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
    Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia.
    Han K; Wang Q; Cao H; Qiu G; Cao J; Li X; Wang J; Shen B; Zhang J
    Oncotarget; 2016 Apr; 7(17):23812-24. PubMed ID: 26993774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing of dasatinib by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2011 Apr; 56(4):595-603. PubMed ID: 21298745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
    McMillin DW; Jacobs HM; Delmore JE; Buon L; Hunter ZR; Monrose V; Yu J; Smith PG; Richardson PG; Anderson KC; Treon SP; Kung AL; Mitsiades CS
    Mol Cancer Ther; 2012 Apr; 11(4):942-51. PubMed ID: 22246439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
    Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 Jun; 58(6):916-23. PubMed ID: 21584937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
    Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
    Houghton PJ; Gorlick R; Kolb EA; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Feb; 58(2):191-9. PubMed ID: 21337679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
    Swords RT; Kelly KR; Smith PG; Garnsey JJ; Mahalingam D; Medina E; Oberheu K; Padmanabhan S; O'Dwyer M; Nawrocki ST; Giles FJ; Carew JS
    Blood; 2010 May; 115(18):3796-800. PubMed ID: 20203261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
    Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
    Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
    Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
    Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.
    Yang D; Tan M; Wang G; Sun Y
    PLoS One; 2012; 7(3):e34079. PubMed ID: 22457814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
    Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM
    Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
    Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.